2026-2034年全球医药和生物技术领域人工智慧（AI）市场规模、份额、趋势和成长分析报告

预计到 2025 年，医药和生物技术领域的人工智慧 (AI) 市场规模将达到 106.5 亿美元，到 2034 年将达到 367 亿美元，2026 年至 2034 年的复合年增长率为 14.74%。

随着人工智慧技术革新药物发现、临床试验和研究方法，全球製药和生物技术领域的人工智慧市场正经历快速成长。人工智慧使製药公司能够分析大量资料集，识别有前景的候选药物，并加速新治疗方法的开发。这种能力显着降低了研究时间和成本，使人工智慧成为现代製药创新中不可或缺的工具。

製药和生技公司正在加强与科技公司的合作，将人工智慧融入研发流程中。人工智慧应用，例如预测分析、机器学习和数据建模，正在提高药物研发的准确性和临床试验结果的精确度。这些技术有助于优化研究策略，提高药物研发效率。

未来几年，随着人工智慧技术的不断发展并与先进的生物医学研究相结合，市场预计将显着扩张。对数位医疗和计算生物学领域投资的增加，进一步巩固了人工智慧在药物创新中的作用。随着对更快、更有效率的药物研发需求的日益增长，人工智慧在製药和生物技术领域的应用预计将加速推进。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球人工智慧（AI）市场在製药和生物技术领域的细分：按组件划分

• 市场分析、洞察与预测
• 软体
• 硬体
• 服务

第五章：全球人工智慧（AI）在製药和生物技术领域的市场：按应用划分

• 市场分析、洞察与预测
• 药物发现
• 临床试验
• 个人化医疗
• 诊断
• 其他的

第六章：全球人工智慧（AI）在製药和生物技术领域的市场：按部署模式划分

• 市场分析、洞察与预测
• 现场
• 云

第七章：全球製药和生物技术产业人工智慧（AI）市场：按最终用户划分

• 市场分析、洞察与预测
• 製药公司
• 生技公司
• 研究机构
• 其他的

第八章：全球医药和生物技术产业人工智慧（AI）市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • IBM Watson Health
  • Google DeepMind
  • Microsoft Genomics
  • NVIDIA Corporation
  • Atomwise
  • BenevolentAI
  • Insilico Medicine
  • Exscientia
  • BioXcel Therapeutics
  • CureMetrix
  • PathAI
  • Recursion Pharmaceuticals

The AI in Pharma and Biotech Market size is expected to reach USD 36.70 Billion in 2034 from USD 10.65 Billion (2025) growing at a CAGR of 14.74% during 2026-2034.

The global AI in pharma and biotech market is experiencing rapid growth as artificial intelligence technologies transform drug discovery, clinical trials, and research processes. AI enables pharmaceutical companies to analyze vast datasets, identify potential drug candidates, and accelerate the development of new treatments. This capability significantly reduces research time and costs, making AI an essential tool in modern pharmaceutical innovation.

Pharmaceutical and biotechnology companies are increasingly partnering with technology firms to integrate AI into their research and development operations. AI applications such as predictive analytics, machine learning, and data modeling are improving the accuracy of drug development and clinical trial outcomes. These technologies are helping organizations optimize research strategies and improve the efficiency of pharmaceutical development.

In the coming years, the market is expected to expand significantly as AI technologies continue to evolve and integrate with advanced biomedical research. Growing investments in digital healthcare and computational biology are further strengthening the role of AI in pharmaceutical innovation. As the demand for faster and more efficient drug development increases, AI adoption in the pharma and biotech sectors is likely to accelerate.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Component

• Software
• Hardware
• Services

By Application

• Drug Discovery
• Clinical Trials
• Personalized Medicine
• Diagnostics
• Others

By Deployment Mode

• On-Premises
• Cloud

By End-User

• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Others

COMPANIES PROFILED

• IBM Watson Health, Google DeepMind, Microsoft Genomics, NVIDIA Corporation, Atomwise, BenevolentAI, Insilico Medicine, Exscientia, BioXcel Therapeutics, CureMetrix, PathAI, Recursion Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY COMPONENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Component
• 4.2. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hardware Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Drug Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinical Trials Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY DEPLOYMENT MODE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Deployment Mode
• 6.2. On-Premises Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cloud Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Component
  • 8.2.2 By Application
  • 8.2.3 By Deployment Mode
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Component
  • 8.3.2 By Application
  • 8.3.3 By Deployment Mode
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Component
  • 8.4.2 By Application
  • 8.4.3 By Deployment Mode
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Component
  • 8.5.2 By Application
  • 8.5.3 By Deployment Mode
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Component
  • 8.6.2 By Application
  • 8.6.3 By Deployment Mode
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AI IN PHARMA AND BIOTECH INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 IBM Watson Health
  • 10.2.2 Google DeepMind
  • 10.2.3 Microsoft Genomics
  • 10.2.4 NVIDIA Corporation
  • 10.2.5 Atomwise
  • 10.2.6 BenevolentAI
  • 10.2.7 Insilico Medicine
  • 10.2.8 Exscientia
  • 10.2.9 BioXcel Therapeutics
  • 10.2.10 CureMetrix
  • 10.2.11 PathAI
  • 10.2.12 Recursion Pharmaceuticals